Your browser doesn't support javascript.
loading
Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions.
Lam, Isabel; Ndayisaba, Alain; Lewis, Amanda J; Fu, YuHong; Sagredo, Giselle T; Kuzkina, Anastasia; Zaccagnini, Ludovica; Celikag, Meral; Sandoe, Jackson; Sanz, Ricardo L; Vahdatshoar, Aazam; Martin, Timothy D; Morshed, Nader; Ichihashi, Toru; Tripathi, Arati; Ramalingam, Nagendran; Oettgen-Suazo, Charlotte; Bartels, Theresa; Boussouf, Manel; Schäbinger, Max; Hallacli, Erinc; Jiang, Xin; Verma, Amrita; Tea, Challana; Wang, Zichen; Hakozaki, Hiroyuki; Yu, Xiao; Hyles, Kelly; Park, Chansaem; Wang, Xinyuan; Theunissen, Thorold W; Wang, Haoyi; Jaenisch, Rudolf; Lindquist, Susan; Stevens, Beth; Stefanova, Nadia; Wenning, Gregor; van de Berg, Wilma D J; Luk, Kelvin C; Sanchez-Pernaute, Rosario; Gómez-Esteban, Juan Carlos; Felsky, Daniel; Kiyota, Yasujiro; Sahni, Nidhi; Yi, S Stephen; Chung, Chee Yeun; Stahlberg, Henning; Ferrer, Isidro; Schöneberg, Johannes; Elledge, Stephen J.
Afiliación
  • Lam I; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; H
  • Ndayisaba A; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; H
  • Lewis AJ; École Polytechnique Fédérale de Lausanne and University of Lausanne, Lausanne, Switzerland.
  • Fu Y; The University of Sydney Brain and Mind Centre and Faculty of Medicine and Health School of Medical Science, Sydney, NSW, Australia.
  • Sagredo GT; The University of Sydney Brain and Mind Centre and Faculty of Medicine and Health School of Medical Science, Sydney, NSW, Australia.
  • Kuzkina A; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; H
  • Zaccagnini L; Dementia Research Institute, University College London, London, UK.
  • Celikag M; Dementia Research Institute, University College London, London, UK.
  • Sandoe J; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Sanz RL; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; H
  • Vahdatshoar A; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Martin TD; Harvard Medical School, Boston, MA, USA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Morshed N; Harvard Medical School, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Boston Children's Hospital, Boston, MA, USA; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Ichihashi T; Nikon Corporation, Tokyo, Japan.
  • Tripathi A; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Ramalingam N; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Oettgen-Suazo C; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Bartels T; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Boussouf M; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Schäbinger M; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Hallacli E; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; H
  • Jiang X; Yumanity Therapeutics, Cambridge, MA, USA.
  • Verma A; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Tea C; University of California, San Diego, San Diego, CA, USA.
  • Wang Z; University of California, San Diego, San Diego, CA, USA.
  • Hakozaki H; University of California, San Diego, San Diego, CA, USA.
  • Yu X; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Hyles K; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Park C; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
  • Wang X; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA; Division of Movement Disorders, American Parkinson Disease Association (APDA) Center for Advanced Research and MSA Center of Excellence, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; H
  • Theunissen TW; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Wang H; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Jaenisch R; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
  • Lindquist S; Whitehead Institute for Biomedical Research, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Stevens B; Harvard Medical School, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Boston Children's Hospital, Boston, MA, USA; The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Stefanova N; Division of Neurobiology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Wenning G; Division of Neurobiology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • van de Berg WDJ; Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands.
  • Luk KC; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Sanchez-Pernaute R; BioBizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
  • Gómez-Esteban JC; BioBizkaia Health Research Institute, Barakaldo, Spain.
  • Felsky D; Centre for Addiction and Mental Health, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.
  • Kiyota Y; Nikon Corporation, Tokyo, Japan.
  • Sahni N; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Baylor College of Medicine, Houston, TX, USA.
  • Yi SS; The University of Texas at Austin, Austin, TX, USA.
  • Chung CY; Yumanity Therapeutics, Cambridge, MA, USA.
  • Stahlberg H; École Polytechnique Fédérale de Lausanne and University of Lausanne, Lausanne, Switzerland.
  • Ferrer I; The University of Barcelona, Institut d'Investigacio Biomedica de Bellvitge IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Schöneberg J; University of California, San Diego, San Diego, CA, USA.
  • Elledge SJ; Harvard Medical School, Boston, MA, USA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Neuron ; 112(17): 2886-2909.e16, 2024 Sep 04.
Article en En | MEDLINE | ID: mdl-39079530
ABSTRACT
The heterogeneity of protein-rich inclusions and its significance in neurodegeneration is poorly understood. Standard patient-derived iPSC models develop inclusions neither reproducibly nor in a reasonable time frame. Here, we developed screenable iPSC "inclusionopathy" models utilizing piggyBac or targeted transgenes to rapidly induce CNS cells that express aggregation-prone proteins at brain-like levels. Inclusions and their effects on cell survival were trackable at single-inclusion resolution. Exemplar cortical neuron α-synuclein inclusionopathy models were engineered through transgenic expression of α-synuclein mutant forms or exogenous seeding with fibrils. We identified multiple inclusion classes, including neuroprotective p62-positive inclusions versus dynamic and neurotoxic lipid-rich inclusions, both identified in patient brains. Fusion events between these inclusion subtypes altered neuronal survival. Proteome-scale α-synuclein genetic- and physical-interaction screens pinpointed candidate RNA-processing and actin-cytoskeleton-modulator proteins like RhoA whose sequestration into inclusions could enhance toxicity. These tractable CNS models should prove useful in functional genomic analysis and drug development for proteinopathies.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cuerpos de Inclusión / Alfa-Sinucleína / Células Madre Pluripotentes Inducidas Límite: Humans Idioma: En Revista: Neuron Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cuerpos de Inclusión / Alfa-Sinucleína / Células Madre Pluripotentes Inducidas Límite: Humans Idioma: En Revista: Neuron Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article